TEVA, US8816242098

TEVA stock: At USD 41.40, TEVA stock sits 1.48 percent below its 52-week high

Published on 10/16/2026 at 17:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TEVA stock costs USD 41.40 on October 16, 2026, up 0.71 percent on Nasdaq. Oppenheimer set a USD 52.00 target on October 9, 2026.

Analyst target and trading position

Oppenheimer raised its Teva target to USD 52.00 on October 9, 2026.
Teva is scheduled to report third-quarter results on November 3, 2026.
TEVA stock stood at USD 41.40 on the NYSE on October 16, 2026 at 11:08 a.m. ET, up 0.71 percent versus the prior close.
Teva's market capitalization was USD 48.2 billion and its price-to-earnings ratio was 68.99.

TEVA, US8816242098, Illustration mit AI erstellt.

At USD 41.40, Teva (US8816242098) stock stood 1.48 percent below its 52-week high on October 16, 2026. Investing.com reported that Oppenheimer raised its target from USD 50.00 to USD 52.00 on October 9, 2026. Teva stock was up 0.71 percent at USD 41.40 on the NYSE at 11:08 a.m. ET.

November 3 results are next

Teva's next scheduled corporate event is its third-quarter 2026 results release on November 3, 2026. The company said in an investor release that the announcement is due before the market opens, followed by a conference call at 8:00 a.m. ET. Teva also identified the release as part of its third-quarter reporting calendar.

The stock remains near its high

Teva's 52-week range was USD 18.83 to USD 42.02 as of October 16, 2026. The current price was 119.97 percent above the low and 1.48 percent below the high, placing the stock near the upper end of its yearly range. Trading volume was 952,166 shares, compared with an average volume of 5,684,610 shares.

What does USD 52.00 imply?

Oppenheimer's USD 52.00 target was 25.60 percent above the USD 41.40 price on October 16, 2026. The target followed regulatory approval for Teva's once-monthly olanzapine treatment, but this report treats the price position rather than assigning a cause to the daily move.

Valuation and peer comparison

Teva had a market capitalization of USD 48.2 billion and a price-to-earnings ratio of 68.99 as of October 16, 2026. The upcoming November 3 reporting date gives the valuation its next scheduled checkpoint.

Comparison with peers

TEVA (NYSE, USD): plus 0.71 percent, P/E 68.99, market capitalization USD 48.2 billion
Bristol-Myers Squibb (NYSE, USD): plus 0.51 percent, P/E 13.40, market capitalization USD 124.4 billion
Viatris (NYSE, USD): plus 1.18 percent, market capitalization USD 21.2 billion

Trading position

Teva stood at USD 41.40 on the NYSE on October 16, 2026 at 11:08 a.m. ET, up 0.71 percent versus the prior close. Its position 1.48 percent below the 52-week high leaves the November 3 results date as the next scheduled market checkpoint.